Aktienanalyse zu Aixcrypto Holdings Inc (AIXC)AIXCAixcrypto Holdings Inc

AIxCrypto Holdings, Inc., formerly Qualigen Therapeutics, Inc., is focused on building an ecosystem that integrates Artificial Intelligence (AI) and blockchain, bridging Web2 and Web3. This ecosystem unites a decentralized protocol, distributed network, AI DePIN and EAI RWA value regeneration, and a DeAI Agent product and technology platform designed to achieve optimal trading performance. Its core products include the BesTrade DeAI Agent and the AIxC ecosystem products. Its crypto business, CXC10, is centered on three growth engines which include six key products: C - Crypto 10 (C10) as Value Anchor, X - DeAI Agent, and C - RWA & Ecosystem Tokens. C - Crypto 10 (C10) as Value Anchor - through the C10 Digital Asset Treasury, C10 Index, and a potential C10 ETF. C - RWA & Ecosystem Tokens - including the C10 Stablecoin and the EAI + Crypto Dual-Bridge Real World Asset product, bridging traditional assets with Web3. It also develops and commercializes oncology and immunology therapies. It operates in the Technology sector.

Aixcrypto Holdings Inc is not a good buy right now due to its current price of 0.78, which is significantly down 67.38% year-to-date and 75.61% over the past year. The RSI is at 35.96, indicating that the stock is in the oversold territory, but the overall financial performance shows consistent losses with a net income of -12,289,953 in Q4 2025. The main risk is the high volatility in digital asset management, as indicated by a net loss of 1.9 million in Q1 2026, which could further impact the stock's performance.